ZVIA vs. CGTX, CUE, VTVT, MNOV, SHLT, TPST, CRVS, HYPR, ASRT, and GRTS
Should you be buying Zevia PBC stock or one of its competitors? The main competitors of Zevia PBC include Cognition Therapeutics (CGTX), Cue Biopharma (CUE), vTv Therapeutics (VTVT), MediciNova (MNOV), SHL Telemedicine (SHLT), Tempest Therapeutics (TPST), Corvus Pharmaceuticals (CRVS), Hyperfine (HYPR), Assertio (ASRT), and Gritstone bio (GRTS). These companies are all part of the "medical" sector.
Cognition Therapeutics (NASDAQ:CGTX) and Zevia PBC (NYSE:ZVIA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Cognition Therapeutics presently has a consensus price target of $6.67, suggesting a potential upside of 235.01%. Zevia PBC has a consensus price target of $4.17, suggesting a potential upside of 402.01%. Given Cognition Therapeutics' higher probable upside, analysts clearly believe Zevia PBC is more favorable than Cognition Therapeutics.
Cognition Therapeutics has a net margin of 0.00% compared to Cognition Therapeutics' net margin of -12.91%. Cognition Therapeutics' return on equity of -29.55% beat Zevia PBC's return on equity.
Zevia PBC has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Zevia PBC, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zevia PBC had 1 more articles in the media than Cognition Therapeutics. MarketBeat recorded 2 mentions for Zevia PBC and 1 mentions for Cognition Therapeutics. Zevia PBC's average media sentiment score of 1.80 beat Cognition Therapeutics' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.
Cognition Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Zevia PBC has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500.
43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 53.2% of Zevia PBC shares are held by institutional investors. 23.8% of Cognition Therapeutics shares are held by company insiders. Comparatively, 11.7% of Zevia PBC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Zevia PBC received 7 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 53.33% of users gave Cognition Therapeutics an outperform vote while only 34.09% of users gave Zevia PBC an outperform vote.
Summary
Zevia PBC beats Cognition Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Zevia PBC News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVIA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevia PBC Competitors List
Related Companies and Tools
